Please wait while the formulary information is being retrieved.
KISQALI (RIBOCICLIB SUCCINATE)
- Hr(+), HEr2(-) advanced female breast cancer
200 mg/day (200 mg x 1) tablet
- 1 tablet (200 mg) by oral route once daily at approximately the same time each day on days 1 through 21 of a 28 day treatment cycle
400 mg/day (200 mg x 2) tablet
- 2 tablets (400 mg) by oral route once daily at approximately thesame time each day on days 1 through 21 of a 28 day treatment cycle
600 mg/day (200 mg x 3) tablet
- 3 tablets (600 mg) by oral route once daily at approximately thesame time each day on days 1 through 21 of a 28 day treatment cycle
Hr(+), HEr2(-) advanced female breast cancer
- 1 tablet (200 mg) by oral route once daily at approximately the same time each day on days 1 through 21 of a 28 day treatment cycle
- 2 tablets (400 mg) by oral route once daily at approximately thesame time each day on days 1 through 21 of a 28 day treatment cycle
- 3 tablets (600 mg) by oral route once daily at approximately thesame time each day on days 1 through 21 of a 28 day treatment cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- alfuzosin
- avanafil
- BCG vaccine, live (PF)
- Brilinta
- bromocriptine
- cabergoline
- Cafergot
- Camptosar
- conivaptan in 5 % dextrose
- Cycloset
- D.h.e.45
- Detrol La
- dihydroergotamine
- dronedarone
- dutasteride-tamsulosin
- eplerenone
- ergoloid
- Ergomar
- ergotamine tartrate
- ergotamine-caffeine
- Flomax
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- Inspra
- irinotecan
- Jalyn
- Juxtapid
- Kombiglyze Xr
- Levitra
- lomitapide
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- methylergonovine
- Migergot
- Migranal
- Multaq
- natalizumab
- Parlodel
- Proquad (pf)
- Rapaflo
- Rotateq Vaccine
- rotavirus vaccine live, penta
- Samsca
- saxagliptin-metformin
- silodosin
- Stendra
- tamsulosin
- ticagrelor
- tolterodine
- tolvaptan
- typhoid vaccine
- Tysabri
- Uroxatral
- Vaprisol
- vardenafil
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- A-methapred
- Abstral
- Actiq
- Advair Diskus
- Advair Hfa
- Afinitor
- Afinitor Disperz
- Alfenta
- alfentanil
- Aristospan Intra-articular
- Aristospan Intralesional
- azelastine-fluticasone
- Breo Ellipta
- budesonide
- budesonide-formoterol
- clozapine
- Clozaril
- colchicine
- colchicine-probenecid
- Colcrys
- deferiprone
- Depo-medrol
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- Duragesic
- Dymista
- Endocet
- Endodan
- Entocort Ec
- everolimus
- Ez Use Joint-tunnel-trigger
- Fazaclo
- fentanyl
- fentanyl citrate
- fentanyl citrate (PF)
- Fentora
- Ferriprox
- Flo-pred
- Flonase
- Flovent Diskus
- Flovent Hfa
- fluticasone
- fluticasone furoate
- fluticasone-salmeterol
- fluticasone-vilanterol
- guanfacine
- ibuprofen-oxycodone
- Intuniv Er
- Kenalog
- Korlym
- Lazanda
- macitentan
- Medrol
- Medrol (pak)
- methylprednisolone
- methylprednisolone acetate
- methylprednisolone sod suc(PF)
- methylprednisolone sodium succ
- methylprednisolone-bupivacaine
- mifepristone
- Millipred
- Millipred Dp
- Nasacort
- Nasacort Aq
- Oleptro Er
- Olysio
- Opsumit
- Orapred
- Orapred Odt
- Oxecta
- oxycodone
- oxycodone-acetaminophen
- oxycodone-aspirin
- Oxycontin
- Pediapred
- Percocet
- Percodan
- Physicians Ez Use M-pred
- prednisolone
- prednisolone acetate
- prednisolone sodium phosphate
- prednisone
- Prednisone Intensol
- Primlev
- Pulmicort
- Pulmicort Flexhaler
- quetiapine
- Rayos
- Rhinocort Aqua
- Roxicet
- Seroquel
- Seroquel Xr
- simeprevir
- Solu-medrol
- Solu-medrol (pf)
- Sublimaze (pf)
- Subsys
- Symbicort
- Tenex
- trazodone
- triamcinolone acetonide
- triamcinolone hexacetonide
- triamcinolone-lidocaine
- Uceris
- Veramyst
- Veripred 20
- Versacloz
- Xartemis Xr
- Zortress
Severe
Moderate
- Abilify
- Abilify Discmelt
- Abilify Maintena
- Adcirca
- Ambien
- Ambien Cr
- aripiprazole
- artemether-lumefantrine
- bosentan
- Cialis
- cilostazol
- Coartem
- darifenacin
- Detrol
- Edluar
- Enablex
- eszopiclone
- fesoterodine
- Fetzima
- Intermezzo
- Istodax
- ivacaftor
- Kalydeco
- levomilnacipran
- Lunesta
- mefloquine
- Onglyza
- Pletal
- pomalidomide
- Pomalyst
- regorafenib
- Revatio
- romidepsin
- saxagliptin
- sildenafil
- solifenacin
- Stivarga
- tadalafil
- Toviaz
- Tracleer
- Vesicare
- Viagra
- zolpidem
- Zolpimist
- 30 day risk period post-myocardial infarction
- Congenital long QT syndrome
- Interstitial lung disease
- Lactating mother
- Torsades de pointes
Contraindicated
- Abnormal hepatic function tests
- Chronic heart failure
- Neutropenic disorder
- Pregnancy
Severe
Moderate
- Hypokalemia
- Hypomagnesemia
KISQALI (RIBOCICLIB SUCCINATE)
- Hr(+), HEr2(-) advanced female breast cancer
- Infection
- Leukopenia
- Neutropenic disorder
- Alopecia
- Back pain
- Constipation
- Cough
- Diarrhea
- Fatigue
- Nausea
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Anemia
- Hyperbilirubinemia
- Hypocalcemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Lymphopenia
- Thrombocytopenic disorder
- Acute abdominal pain
- Anorexia
- Dry skin
- Dyspepsia
- Dyspnea
- Eye tearing
- Fever
- General weakness
- Insomnia
- Pain in oropharynx
- Peripheral edema
- Pruritus of skin
- Stomatitis
- Syncope
- Urinary tract infection
- Vitiligo
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Interstitial lung disease
- Interstitial pneumonitis
- Prolonged QT interval
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Ribociclib
No established safety and efficacy.
- 1 Day – 18 Years
- No established safety and efficacy.
Ribociclib
- Severity Level:
D
- Additional Notes: Based on drug pharmacology and animal data dev tox may occur
Contraindicated
Ribociclib
Insufficient human data available; due to potential adverse effects, not rec
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient human data available; due to potential adverse effects, not rec |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Hr(+), HEr2(-) advanced female breast cancer | |
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| Z17.0 | Estrogen receptor positive status [Er+] |
| Z19.1 | Hormone sensitive malignancy status |
| 0-9 | A-Z |
|---|---|
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| Z17.0 | Estrogen receptor positive status [Er+] |
| Z19.1 | Hormone sensitive malignancy status |
Formulary Reference Tool